PMID- 25227564
OWN - NLM
STAT- MEDLINE
DCOM- 20150728
LR  - 20181202
IS  - 1879-1379 (Electronic)
IS  - 0022-3956 (Linking)
VI  - 59
DP  - 2014 Dec
TI  - L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a 
      double-blind, placebo-controlled, randomized trial.
PG  - 125-31
LID - S0022-3956(14)00252-0 [pii]
LID - 10.1016/j.jpsychires.2014.08.016 [doi]
AB  - Increasing evidence suggest that the nitric oxide signaling system of the brain 
      may contribute to the pathophysiology of schizophrenia, making this system a 
      target for development of novel therapeutics. The objective of this study was to 
      investigate the efficacy and safety of L-lysine as an adjunctive to risperidone 
      in the treatment of patients with chronic schizophrenia during an 8-week trial. 
      Seventy-two chronic schizophrenia inpatients with a Positive and Negative 
      Syndrome Scale (PANSS) total score of >/= 60 participated in a randomized, 
      double-blind, placebo-controlled trial in the active phase of their disease and 
      underwent 8 weeks of treatment with either L-lysine (6 g/day) or placebo as an 
      adjunctive to risperidone. Patients were evaluated using PANSS and its subscales 
      at baseline and weeks 2, 4, 6 and 8. The primary outcome measure was to evaluate 
      the efficacy of L-lysine in improving schizophrenia symptoms. Repeated measures 
      analysis demonstrated significant effect for time x treatment interaction on the 
      PANSS total (P < 0.001), negative (P < 0.001) and general psychopathology (P < 
      0.001) subscale scores but not the PANSS positive subscale scores (P = 0.61). The 
      frequency of adverse events (AEs) did not differ significantly between the two 
      treatment groups and no serious AE was observed. The present study demonstrated 
      that l-lysine can be a tolerable and efficacious adjunctive therapy for improving 
      negative and general psychopathology symptoms in chronic schizophrenia. However, 
      the safety and efficacy of higher doses of l-lysine and longer treatment periods 
      still remain unknown. TRIAL REGISTRATION: Iranian registry of clinical trials 
      (www.irct.ir): IRCT201202201556N33.
CI  - Copyright (c) 2014 Elsevier Ltd. All rights reserved.
FAU - Zeinoddini, Atefeh
AU  - Zeinoddini A
AD  - Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Ahadi, Morvarid
AU  - Ahadi M
AD  - Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Farokhnia, Mehdi
AU  - Farokhnia M
AD  - Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Rezaei, Farzin
AU  - Rezaei F
AD  - Department of Psychiatry, Kurdistan University of Medical Sciences, Sanandaj, 
      Iran.
FAU - Tabrizi, Mina
AU  - Tabrizi M
AD  - Department of Medical Genetics, Tehran University of Medical Sciences, Tehran, 
      Iran.
FAU - Akhondzadeh, Shahin
AU  - Akhondzadeh S
AD  - Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical 
      Sciences, Tehran, Iran. Electronic address: s.akhond@neda.net.
LA  - eng
SI  - IRCT/IRCT201202201556N33
PT  - Address
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140906
PL  - England
TA  - J Psychiatr Res
JT  - Journal of psychiatric research
JID - 0376331
RN  - 0 (Antipsychotic Agents)
RN  - K3Z4F929H6 (Lysine)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/*therapeutic use
MH  - Chronic Disease
MH  - Depression/drug therapy/etiology
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lysine/*therapeutic use
MH  - Male
MH  - Psychiatric Status Rating Scales
MH  - Risperidone/*therapeutic use
MH  - Schizophrenia/complications/*drug therapy
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Clinical trial
OT  - Nitric oxide
OT  - PANSS
OT  - Schizophrenia
OT  - l-lysine
EDAT- 2014/09/18 06:00
MHDA- 2015/07/29 06:00
CRDT- 2014/09/18 06:00
PHST- 2014/05/06 00:00 [received]
PHST- 2014/07/23 00:00 [revised]
PHST- 2014/08/21 00:00 [accepted]
PHST- 2014/09/18 06:00 [entrez]
PHST- 2014/09/18 06:00 [pubmed]
PHST- 2015/07/29 06:00 [medline]
AID - S0022-3956(14)00252-0 [pii]
AID - 10.1016/j.jpsychires.2014.08.016 [doi]
PST - ppublish
SO  - J Psychiatr Res. 2014 Dec;59:125-31. doi: 10.1016/j.jpsychires.2014.08.016. Epub 
      2014 Sep 6.